Performance of Prognostic Scores and Staging Systems in Predicting Long-Term Survival Outcomes After Surgery for Intrahepatic Cholangiocarcinoma by Buettner, S et al.
Received: 21 April 2017 | Accepted: 15 June 2017
DOI: 10.1002/jso.24759
RESEARCH ARTICLE
Performance of prognostic scores and staging systems in
predicting long-term survival outcomes after surgery for
intrahepatic cholangiocarcinoma
Stefan Buettner1,2 | Boris Galjart2 | Jeroen L. A. van Vugt MD2 |
Fabio Bagante MD1 | Sorin Alexandrescu MD3 | Hugo P. Marques MD4 |
Jorge Lamelas MD4 | Luca Aldrighetti MD5 | T. Clark Gamblin MD6 |
Shishir K. Maithel MD7 | Carlo Pulitano MD8 | Georgios A. Margonis MD, PhD1 |
Matthew Weiss MD1 | Todd W. Bauer MD9 | Feng Shen MD10 |
George A. Poultsides MD11 | J. Wallis Marsh MD12 | Jan N. M. IJzermans MD2 |
Bas Groot Koerkamp MD, PhD2 | Timothy M. Pawlik MD, MPH, PhD1,13
1Department of Surgery, Johns Hopkins
Hospital, Baltimore, Maryland
2Department of Surgery, Erasmus MC
University Medical Center, Rotterdam, The
Netherlands
3 Fundeni Clinical Institute, Bucharest,
Romania
4Curry Cabral Hospital, Lisbon, Portugal
5Ospedale San Raffaele, Milan, Italy
6Medical College of Wisconsin, Milwaukee,
Wisconsin
7 Emory University, Atlanta, Georgia
8University of Sydney, Sydney, Australia
9University of Virginia, Charlottesville,
Virginia
10 Eastern Hepatobiliary Surgery Hospital,
Shanghai, China
11 Stanford University, Stanford, California
12University of Pittsburgh Medical Center,
Pittsburgh, Pennsylvania
13 The Ohio State University Wexner Medical
Center, Columbus, Ohio
Correspondence
Timothy M. Pawlik, MD, MPH, PhD, FACS,
Professor and Chair, Department of Surgery,
The Urban Meyer III and Shelley Meyer Chair
for Cancer Research, The Ohio State University
Wexner Medical Center, 395 W. 12th Avenue,
Suite 670, Columbus, OH 43210.
Email: tim.pawlik@osumc.edu
Introduction:Wesought to validate the commonly usedprognosticmodels and staging
systems for intrahepatic cholangiocarcinoma (ICC) in a large multi-center patient
cohort.
Methods: The overall (OS) and disease free survival (DFS) prognostic discriminatory
ability of various commonly usedmodelswere assessed in a large retrospective cohort.
Harrell’s concordance index (c-index) was used to determine accuracy of model
prediction.
Results:Among 1054 ICC patients, median OSwas 37.7 months and 1-, 3-, and 5-year
survival, were 78.8%, 51.5%, and 39.3%, respectively. Recurrence of disease occurred
in 454 (43.0%) patients with a median DFS of 29.6 months. One-, 3-, and 5- year DFS
were 64.6%, 46.5%, and 44.4%, respectively. The prognostic models associated with
the best OS prediction were the Wang nomogram (c-index 0.668) and the Nathan
staging system (c-index 0.639). No model was proficient in predicting DFS. Only the
Wangnomogramexceededa c-indexof 0.6 forDFS (c-index0.602). The c-index for the
AJCC staging system was 0.637 for OS and 0.582 for DFS.
Conclusions:While theWang nomogram had the best discriminatory ability relative to
OS and DFS, no ICC staging system or nomogram demonstrated excellent prognostic
discrimination. The AJCC staging for ICC performed reasonably, although its overall
discrimination was only modest-to-good.
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1 | INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) occurs in approximately 1-2
per 100 000 persons, making it the second most common primary
hepatic malignancy.1–3 Although ICC mostly develops as a well-
differentiated carcinoma, only a minority (15%) of patients presents
with resectable disease at the time of diagnosis.4 Complete surgical
resection remains the only option for cure. The estimated median
survival after resection of ICC ranges from 27 to 36 months.5–9
Postoperative survival estimates for individual patients can have
consequences with regards to surveillance strategies and decisions
about adjuvant chemotherapy.10
The most common staging for ICC is the TNM system in the
American Joint Committee on Cancer (AJCC) staging manual.11
While the AJCC staging system is widely adopted, TNM categoriza-
tion can be limited in providing individual patient-specific prognosis
among patients with biliary cancers. As such, several groups have
proposed new prognostic models and nomograms.12,13 In addition,
some groups including the Liver Cancer Study Group of Japan
(LCSGJ),14 the Society of Hepatobiliary Surgery Japan (SHPBSJ),15
Okabayashi et al,16 and Nathan et al17 have offered a wide range of
different staging systems that have been proposed to discriminate
overall survival (OS) better. External validation of these proposed
prognostic staging schemes has been largely lacking, however. When
developing a prediction model, there is an inherent risk of
overestimating both its accuracy and generalizability. External
validation of any staging proposal is therefore necessary in large,
multicenter cohorts of patients. Since only a few prognostic ICC
models have been tested in such cohorts, further evaluation of these
models is important. As such, the objective of the current study was
to define the predictive ability of the available proposed prognostic
models for patients with resected ICC in a large cohort of patients
from multiple international high-volume centers.
2 | METHODS
All patients undergoing resection for ICC between January 1, 1990 and
July 1, 2016 at one of 12 participating major hepatobiliary institutions
in the United States, Asia, Oceania, and Europe were identified (Johns
Hopkins University, Baltimore, Maryland; Emory University, Atlanta,
Georgia; Stanford University Medical Center, Stanford, California;
University of Virginia Health System, Charlottesville, Virginia; Fundeni
Clinical Institute, Bucharest, Romania; Beaujon Hospital, Clichy,
France; Curry Cabral Hospital, Lisbon, Portugal; Eastern Hepatobiliary
Surgery Hospital, Shanghai, China; Ottowa General Hospital, Ottowa,
Canada; Royal Prince Alfred Hospital, Sydney, Australia; San Raffaele
Hospital, Milan, Italy; Erasmus MC University Medical Center,
Rotterdam, the Netherlands). Patient records in each participating
center were assessed retrospectively and entered into a central
standardized registry for each institution.
Sociodemographic and clinicopathologic data were collected and
included age, sex and race, tumor size, histologic grade, presence of
nodal metastases, final resection margin and the presence of vascular,
and/or perineural invasion. A minor hepatectomy was defined as a
hepatic resection of less than three Couinaud segments. Margin status
was categorized as R0 for tumor negative resection margins, R1 for
microscopically positive margins and R2 for macroscopically positive
margins. Only patients undergoing surgery for histologically confirmed
ICC were included in the study population; patients who did not
undergo resection were excluded. Patients who underwent transplan-
tation were also excluded. The respective institutional review boards
of each participating institution approved this study.
2.1 | Included models
Seven frequently used postoperative nomograms and staging systems
for resected ICC patients were selected for this study. The prognostic
models included those proposed by Wang et al,18 the AJCC TNM 7th
edition,11 Hyder et al,13 Liver Cancer Study Group of Japan (LCSGJ),14
the Society of Hepatobiliary Surgery Japan (SHPBSJ),15 Okabayashi
et al,16 and Nathan et al,17 which are summarized in Table 1.
2.2 | Statistical analysis
Categorical variables were described as whole numbers and percen-
tages while continuous variables were reported as medians with
interquartile (IQR) range. Percentages for each variable were
calculated based on available data, excluding missing values.
Univariable comparison of categorical variables was performed using
the Pearson chi-square test. Univariable comparison of continuous
variables was performed using the Mann-Whitney U-test. In order to
ascertain the validity of the results, additional multiple imputations for
the Wang (51.8% missing) and Hyder (23.9% missing) nomograms
were performed, as these models had a larger amount of missing data.
Since c-indices cannot be pooled using Rubin’s rules, median and range
values were provided.19
The primary outcome of the study was overall survival (OS). The
secondary outcomewas disease-free survival (DFS). OSwas calculated
as the time from the date of surgery to the date of death or date of last
available follow-up, while DFS was calculated from the date of surgery
to the date of first-known radiographically or pathologically confirmed
metastasis. Both survival estimates were determined using the Kaplan-
Meier method. The log-rank test was used to compare the strata of the
prognostic models. Cox regression was performed to evaluate the
effect of well-known prognostic variables in this particular cohort of
patients. Each of the variables included in the models Schoenfeld
residuals were plotted, in order to evaluate if the proportional hazards
assumption was not violated. A sub-analysis among the patients who
had a mass-forming ICC was conducted for the SHPBSJ and
Okabayashi staging systems, because these staging systems were
originally developed in cohorts of patients with mass-forming ICC.15,16
Model performance was assessed using Harrell’s concordance
index (c-index). The c-index provides the probability that, in a randomly
selected pair of patients, inwhich one patient dies before the other, the
patient who died first had the worse predicted outcome from the
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nomogram. Analyses were performed using SPSS 22.0 (IBM, New
York) and R version 3.03 (http://www.r-project.org) with the rms
package. All tests were two-sided and P < 0.05 defined statistical
significance.
3 | RESULTS
3.1 | Cohort description
A total of 1054 patients who underwent resection for ICC andmet the
inclusion criteria were identified (Table 2). Median patient age was
59 years (IQR 51, 68) and the majority of patients were male (n = 568,
53.9%).Most patients had anASA classification of II (n = 486, 52.0%) or
III (n = 274, 29.3%). At the time of surgery, 6 out of 10 patients
underwent a major hepatectomy involving more than three Couinaud
segments (n = 60, 59.9%). Almost half of patients underwent a formal
portal lymphadenectomy (n = 463, 45.1%). On final pathology, the
majority of patients had an R0 resection (n = 882, 86.4%). Morphologi-
cally, most patients had a mass-forming ICC (n = 892; 92.1%), while a
minority had a papillary (n = 31; 3.2%) or periductal infiltrating (n = 45;
4.5%) growth pattern. Lymph nodemetastases were noted in 17.5% of
patients (n = 184).
For each prognostic model, patients were allocated into the
different risk groups, based on disease characteristics (Tables 3
and 4). The number of missing values that resulted in patients
being excluded from analysis was small in most prognostic models.
Specifically, 99 (9.4%) patients were not included in the AJCC
TNM staging, 33 (3.1%) in the LCSGJ staging, 42 (4.0%) in the
SHPBS staging, 25 (2.4%) in the Okabayashi staging, and 91 (8.6%)
in the Nathan staging system. The nomograms by Wang (51.8%
missing) and Hyder (23.9% missing) had a higher proportion of
missing patients. In the Wang nomogram, the median points score
was 40.1 (IQR 23.2, 63.6). One hundred twenty-seven patients
(25.0%) were allocated in the group <23.4 points, 255 (50.1%) in
the group 23.4-64.9, and 127 in the group >64.9. Of note, the
main reason the Wang nomogram could not be determined for a
subset of patients (n = 548), were missing values for both CEA and
CA19-9.
In the AJCC 7th staging schema, the majority of patients were
allocated into stages I and II (n = 692, 72.2%). In the LCSGJ staging
system, almost 6 out of every 10 patients were allocated in stage II
(n = 607, 59.3%), which was identical to the allocation using the
SHPBSJ staging system. In the Okabayashi staging system, 61.8% of
the patients had stage I disease and 299 (29.0%) had stage III disease,
while only 94 patients were allocated into the other stages. In the
staging by Nathan, 398 (41.2%) patients had stage I disease, 360
(37.2%) had stage II disease and 209 (21.6%) had stages III or IV
disease. Patients had an average score of 12.9 (IQR 10.9-15.9) when
using Hyder’s nomogram.
3.2 | Overall survival and disease free survival
After a median follow-up of 27 months, nearly half of patients were
deceased (n = 521, 49.7%).MedianOSwas 37.7months and 1-, 3-, and
5-year survival was 78.8%, 51.5%, and 39.3%, respectively. Recur-
rence of disease occurred in 454 (43.1%) patients during follow-up.
Median disease-free survival was 29.6 months and 1-, 3-, and 5-year
DFS was 64.6%, 46.5%, and 44.4%, respectively.
TABLE 1 Summary of the included prognostic scores and staging systems
Component
Wang
nomogram AJCC 7th LCSGJ staging
Society of
hepatobiliary
surgery Japan Okabayashi
Nathan
staging
Hyder
nomogram
CEA, preoperative 0-100 μg/L – – – – – –
CA 19-9,
preoperative
0-1,000 U/mL – – – – – –
Vascular invasion Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No No, microscopic,
macroscopic
Lymph node
metastases
Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No,
insufficiently
harvested
Direct invasion/local
metastases
Yes/No Yes/No – – Yes/No –
Number of lesions 1, 2-3, ≥4 Solitary,
multiple
Solitary,
multiple
Solitary,
multiple
Solitary,
multiple
Solitary,
multiple
Solitary, multiple
Tumor diameter 0-22 cm – ≤2 cm, >2 cm ≤2 cm, >2 cm – 1-15 cm
Periductal/serosal
invasion
– Yes/No Yes/No – Yes/No –
Distant metastases – Yes/No Yes/No Yes/No Yes/No Yes/No –
Age – – – – – – 25-85 years
Cirrhosis – – – – – – Yes/No
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Components of the prognostic models of interest were
evaluated separately for prognostic ability with regards to OS and
DFS (Table 3). Except for age and cirrhosis, all variables were
associated with OS. Of note, direct invasion of adjacent organs (HR:
2.76, 95%CI 2.11-3.60, P < 0.001) and distant metastases (HR: 2.64,
95%CI 1.67-4.19, P < 0.001) were the factors most strongly
associated with OS. The continuous variable CA19-9 had the best
c-index of 0.634. With regards to DFS, tumor diameter >2 cm was
strongly associated with risk of disease recurrence (HR: 2.10, 95%CI
1.12-3.92). Plotted Schoenfeld residuals demonstrated that the
proportional hazards assumption was not violated for any of the
variables.
3.3 | Comparison of scoring systems
Data on the performance of the models regarding the OS
prediction are presented in Table 4 and Fig. 1; the ability of the
models to predict DFS is presented in Table 5 and Fig. 2. Although
there was a decline in OS and DFS with each progressive stage in
most models, the highest stage was not always associated with the
worst survival. For example, in the higher stages of several models,
no differences in OS and DFS were observed (Figs. 1 and 2). The
Wang nomogram was the only prognostic model in which
incremental, clear differences among the survival curves in the
bottom quartile, interquartile range, and the upper quartile were
identified for both OS and DFS.
The prognostic models providing the best prediction of OS at all
time points were the Wang nomogram and the Nathan staging
system. These prediction methods also yielded the highest
c-statistics (0.668 and 0.639). No model exceeded a c-index of 0.7
for OS. The ability of the models to predict DFS is presented in
Table 5 and Fig. 2. No model was proficient in predicting DFS. The
only model to exceed a c-index of 0.6 for DFS, which indicates fair
discrimination, was the nomogram by Wang et al. For both OS and
DFS, the Hyder nomogram had the lowest predictive capacity. Both
the SHPBSJ (OS c-index: 0.606, DFS c-index: 0.558) and the
Okabayashi staging systems (OS c-index: 0.600, DFS c-index: 0.558)
did not perform better within the mass-forming ICC sub-cohort. The
imputed datasets for the Wang and Hyder nomograms did not
show large differences compared with the complete case analysis.
Specifically, the Wang nomogram had a c-index of 0.674
(0.670-0.680) for OS and 0.601 (0.597-0.604) for DFS, which was
similar to the estimate in the complete-case analysis. For the Hyder
nomogram, the c-index for OS was 0.614 (0.613-0.616) and the
c-index for DFS was 0.542 (0.541-0.548).
TABLE 2 Baseline characteristics of the validation cohort (n = 1,054)
Variable n (%)/median (IQR)
Gender
Male 568 (53.9)
Female 485 (46.1)
Age, years 59 (51-68)
Race
Caucasian 626 (61.6)
African-American 39 (3.8)
Asian 329 (32.4)
Other 22 (2.2)
ASA
I 104 (11.1)
II 486 (52.0)
III 274 (29.3)
IV 71 (7.6)
BMI 25.4 (22.6-28.2)
Period of treatment
1990-2000 35 (3.4)
2001-2005 115 (11.1)
2006-2010 422 (40.8)
2011-2016 463 (44.7)
Type of resection
Minor hepatectomy (<3 segments) 419 (40.9)
Right hepatectomy 167 (16.3)
Left hepatectomy 193 (18.8)
Extended right hepatectomy 128 (12.5)
Extended left hepatectomy 96 (9.4)
Central hepatectomy 21 (2.1)
Number of tumors 1 (1-1)
Morphologic type
Mass-forming 892 (92.1)
Papillary 31 (3.2)
Periductal infiltrating 45 (4.6)
Tumor size (cm) 6.1 (4.3-9.0)
Major vascular invasion 100 (9.7)
Microvascular invasion 257 (25.6)
Perineural invasion 152 (16.4)
Invasion of adjacent organs 77 (7.5)
Satellite lesions 233 (22.6)
Intrahepatic metastases 75 (7.3)
Lymphadenectomy 463 (45.1)
Lymph nodes harvested 2 (0-5)
Lymph node metastases 184 (17.5)
Extrahepatic metastases 40 (3.8)
Margin status
(Continues)
TABLE 2 (Continued)
Variable n (%)/median (IQR)
R0 882 (86.4)
R1 134 (13.1)
R2 5 (0.5)
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4 | DISCUSSION
Prognostic models are frequently used in order to determine
prognosis and predict adverse outcomes in malignant HPB
surgery.18,20–27 Because of the vast difference in characteristics
among individual patients diagnosed with ICC, different approaches
in adjuvant therapy, follow-up, and further surgical treatment can be
tailored to individual patients with the help of these models.12,28–30
In this study, we examined the ability of established nomograms and
staging systems to predict OS and DFS in one of the largest Western
cohorts of ICC to date. We quantified the predictive ability of each
nomogram using Harrell’s concordance index. Although the included
prognostic models varied considerably, some variables were
included in multiple models. Notably, vascular invasion, lymph
node metastases, and number of lesions were included in all
prognostic models. These risk factors had significant prognostic
TABLE 3 Prognostic value of the individual components
Overall survival Disease free survival
Component Hazard ratio 95%CI P-value C-index Hazard ratio 95%CI P-value C-index
CEA, preoperative
Continuous (µg/L) 1.00 1.00-1.00 0.003 0.570 1.00 1.00-1.00 0.001 0.514
CA 19-9, preoperative
Continuous (U/mL) 1.00 1.00-1.00 <0.001 0.634 1.00 1.00-1.00 0.369 0.550
Vascular invasion
No Ref. – – – Ref. – – –
Yes 1.57 1.19-2.06 0.001 0.519 1.59 1.19-2.13 0.002 0.522
Microscopic 1.28 1.02-1.59 0.031 0.91 0.72-1.16 0.451
Macroscopic 1.64 1.24-2.17 <0.001 0.542 1.54 1.15-2.07 0.004 0.521
Lymph node metastases
No Ref. – – – Ref. – – –
Yes 2.48 2.02-3.05 <0.001 0.565 1.62 1.30-2.03 <0.001 0.539
Direct invasion/local metastases
No Ref. – – – Ref. – – –
Yes 2.76 2.11-3.60 <0.001 0.544 1.80 1.27-2.56 <0.001 0.515
Number of lesions
Single Ref. – – – Ref. – – –
Multiple 1.88 1.53-2.30 <0.001 0.551 1.58 1.26-1.97 <0.001 0.534
2-3 1.75 1.39-2.19 <0.001 1.46 1.14-1.89 0.003
≥4 2.45 1.69-3.55 <0.001 0.552 2.13 1.38-3.27 <0.001 0.536
Tumor diameter
Continuous (cm) 1.07 1.04-1.09 <0.001 0.577 1.06 1.03-1.09 <0.001 0.586
≤2 cm Ref. – – – Ref. – – –
>2 cm 2.17 1.22-3.85 0.008 0.513 2.10 1.12-3.92 0.021 0.512
Periductal/serosal invasion
No Ref. – – – Ref. – – –
Yes 2.42 2.01-2.91 <0.001 0.616 1.59 1.31-1.92 <0.001 0.566
Distant metastases
No Ref. – – – Ref. – – –
Yes 2.65 1.67-4.20 <0.001 0.514 1.48 0.81-2.69 0.200 0.505
Age
Continuous (years) 1.00 1.00-1.01 0.384 0.519 0.98 0.97-0.99 <0.001 0.582
Cirrhosis
No Ref. – – – Ref. – – –
Yes 1.01 0.76-1.35 0.939 0.506 1.35 1.02-1.80 0.037 0.522
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TABLE 4 Prediction of overall survival by the included prognostic scores and staging systems
1-Year 3-Year 5-Year
Staging/nomogram
#At risk start
study (%)
Hazard
ratio 95%CI
#At
risk
OS
rate
#At
risk
OS
rate
#At
risk
OS
rate
C-statistic
(SE)
Wang nomogram 0.668
(0.021)*
Cont. 1.01 1.01-1.01
<23.4 129 (25.3) Ref. – 112 91.2 56 78.8 22 66.9
23.4-64.9 260 (51.1) 2.23 1.51-3.29 197 82.9 72 53.6 25 40.8
>64.9 120 (23.6) 4.87 3.22-7.36 68 67.0 13 28.8 3 13.1
AJCC 7th 0.637
(0.021)
I 399 (41.6) Ref. – 328 87.6 165 67.2 76 56.4
II 293 (30.6) 2.10 1.69-2.62 193 78.1 71 42.7 27 27.5
III 63 (6.6) 2.50 1.72-3.63 29 62.3 13 44.1 3 18.5
IV A 161 (16.8) 3.24 2.53-4.15 81 63.4 20 23.9 10 15.4
IV B 42 (4.4) 3.65 2.40-5.54 17 63.3 6 24.1 1 0.1
LCSGJ 0.631
(0.012)
I 29 (2.8) Ref. – 26 96.4 18 88.1 8 78.0
II 607 (59.3) 1.95 1.00-3.78 453 84.0 208 59.7 98 47.9
III 172 (16.8) 3.31 1.68-6.56 107 73.4 46 43.5 18 29.9
IV A 7 (0.7) 5.34 1.78-16.00 5 85.7 0 0.0 0 0.0
IV B 209 (20.4) 5.41 2.75-10.67 90 63.2 20 35.7 6 10.0
Society of hepatobiliary
surgery Japan
0.611
(0.012)
I 29 (2.9) Ref. – 27 96.4 18 88.1 8 78.0
II 607 (59.8) 1.94 1.00-3.78 453 84.0 208 59.7 98 47.9
III 172 (16.9) 3.31 1.67-6.55 107 73.4 46 43.5 18 29.9
IV A 155 (15.3) 5.28 2.66-10.48 73 65.0 14 24.3 3 8.1
IV B 52 (5.1) 5.59 2.65-11.80 19 62.1 5 17.3 3 13.8
Okabayashi 0.607
(0.012)
I 638 (61.8) Ref. – 480 84.5 228 61.4 108 49.5
II 55 (5.3) 1.54 1.03-2.30 32 71.3 15 51.7 4 34.4
III A 130 (12.6) 1.85 1.45-2.37 83 75.0 33 38.5 14 26.8
III B 169 (16.4) 2.77 2.21-3.47 79 64.3 17 24.0 5 9.8
IV 40 (3.9) 3.58 2.24-5.72 11 56.3 3 17.0 1 11.4
Nathan staging 0.639
(0.013)
I 398 (41.2) Ref. – 327 88.0 165 67.9 76 57.0
II 360 (37.2) 2.20 1.79-2.72 225 75.3 85 42.4 31 26.3
III 167 (17.3) 3.42 2.69-4.36 85 63.4 21 22.8 8 11.1
IV 42 (4.3) 4.64 2.90-7.43 11 53.6 3 16.2 1 10.8
Hyder nomogram 0.599
(0.017)*
Cont. 1.09 1.06-1.12
<10.9 191 (23.8) Ref. – 156 86.4 72 68.0 29 59.8
(Continues)
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value in our cohort as well. After evaluating model performance, we
noted that no single model reached the threshold for good
discrimination (ie, a c-index of 0.7) for both OS and DFS. The
most often used AJCC TNM staging system performed reasonable
compare with the other prognostic models (OS c-index: 0.637, DFS
c-index: 0.582). In line with previous studies,10,18 the nomogram by
Wang et al performed the best in predicting OS (c-index 0.668) and
DFS (c-index 0.607).
TABLE 4 (Continued)
1-Year 3-Year 5-Year
Staging/nomogram
#At risk start
study (%)
Hazard
ratio 95%CI
#At
risk
OS
rate
#At
risk
OS
rate
#At
risk
OS
rate
C-statistic
(SE)
10.9-15.9 423 (52.6) 1.30 0.99-1.71 290 82.7 117 55.9 48 44.2
>15.9 190 (23.6) 2.41 1.79-3.25 100 68.5 33 36.8 10 24.5
*C-indices for nomograms were calculated using the continuous score.
FIGURE 1 Overall survival stratified by the different prognostic models. (A) Wang Nomogram Score, (B) AJCC 7th edition stage, (C) LCSGJ
stage, (D) SHPBS stage, (E) Okabayashi stage, (F) Nathan stage, (G) Hyder nomogram score
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TABLE 5 Prediction of disease free survival by the included prognostic scores and staging systems
1-Year 3-Year 5-Year
Staging/nomogram
#At risk start
study (%)
Hazard
ratio 95%CI
#At
risk
DFS
rate
#At
risk
DFS
rate
#At
risk
DFS
rate
C-statistic
(SE)
Wang nomogram 0.607
(0.020)*
Cont. 1.01 1.01-1.01
<23.4 129 (25.3) Ref. – 45 64.0 15 39.1 7 36.5
23.4-64.9 260 (51.1) 1.71 1.22-3.40 59 38.3 17 15.9 8 14.7
>64.9 120 (23.6) 2.59 1.77-3.80 23 31.4 5 10.0 4 10.0
AJCC 7th 0.582
(0.014)
I 399 (41.6) Ref. – 225 69.3 97 51.0 52 48.4
II 293 (30.6) 1.50 1.20-1.88 122 58.8 49 38.6 22 33.8
III 63 (6.6) 1.18 0.73-1.89 20 66.5 9 49.4 6 42.3
IV A 161 (16.8) 1.83 1.42-2.37 54 50.2 21 28.6 15 28.6
IV B 42 (4.4) 2.88 1.83-4.54 9 48.2 1 6.4 1 6.4
LCSGJ 0.562
(0.012)
I 29 (2.8) Ref. – 20 91.3 10 70.3 6 70.3
II 607 (59.3) 1.55 0.80-3.02 323 67.4 153 50.3 98 48.2
III 172 (16.8) 2.06 1.03-4.12 68 60.7 33 41.9 17 36.8
IV A 7 (0.7) 3.65 1.22-10.90 2 33.3 1 33.3 1 33.3
IV B 209 (20.4) 2.56 1.29-5.06 69 53.6 31 31.9 22 31.9
Society of hepatobiliary
surgery Japan
0.563
(0.012)
I 29 (2.9) Ref. – 20 91.3 10 70.3 6 70.3
II 607 (59.8) 1.55 0.80-3.02 323 67.4 155 50.6 98 48.2
III 172 (16.9) 2.06 1.03-4.12 68 60.7 33 41.9 17 36.8
IV A 155 (15.3) 2.51 1.26-5.00 58 54.4 25 32.9 17 32.9
IV B 52 (5.1) 3.19 1.47-6.92
Okabayashi 0.557
(0.012)
I 638 (61.8) Ref. – 343 68.4 166 51.4 106 49.2
II 55 (5.3) 1.35 0.87-2.11 20 60.0 9 46.2 3 38.5
III A 130 (12.6) 1.34 1.02-1.78 54 60.9 27 40.7 15 36.7
III B 169 (16.4) 1.68 1.32-2.13 62 54.1 26 31.3 18 31.3
IV 40 (3.9) 1.70 0.93-3.11 7 50.3 5 35.9 4 35.9
Nathan staging 0.581
(0.013)
I 398 (41.2) Ref. – 224 69.5 97 51.3 52 48.7
II 360 (37.2) 1.48 1.19-1.83 145 60.1 59 39.3 29 34.5
III 167 (17.3) 2.06 1.60-2.65 54 49.0 18 24.7 13 24.7
IV 42 (4.3) 1.47 0.80-2.70 9 56.0 6 42.7 5 42.7
Hyder nomogram 0.521
(0.016)*
Cont. 1.03 1.00-1.06
<10.9 191 (23.8) Ref. – 105 65.8 41 53.9 20 50.4
(Continues)
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ICC prognostic models have been developed in different
populations for different purposes. While the AJCC staging includes
all ICC patients, other models pertain only to patients who have
undergone surgical resection. For example, the nomogram by Wang
et al was designed to predict individual OS after resection of ICC.18
Prognostic factors in this model included CEA, CA19-9, vascular
invasion, presence of lymph nodemetastases, direct invasion and local
metastases, number of tumors, and tumor diameter. A similar
TABLE 5 (Continued)
1-Year 3-Year 5-Year
Staging/nomogram
#At risk start
study (%)
Hazard
ratio 95%CI
#At
risk
DFS
rate
#At
risk
DFS
rate
#At
risk
DFS
rate
C-statistic
(SE)
10.9-15.9 423 (52.6) 1.10 0.84-1.43 201 64.8 93 48.6 56 47.4
>15.9 190 (23.6) 1.25 0.92-1.69 84 61.7 46 42.5 31 42.5
*C-indices for nomograms were calculated using the continuous score.
FIGURE 2 Disease free survival stratified by the different prognostic models. (A) Wang Nomogram Score, (B) AJCC 7th edition stage, (C)
LCSGJ stage, (D) SHPBS stage, (E) Okabayashi stage, (F) Nathan stage, (G) Hyder nomogram score
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nomogramwas developed byHyder et al. Risk factors for survival after
resection in this model included age, number of tumors, tumor
diameter, cirrhosis, lymph node metastases, and macrovascular
invasion.13 A notable feature of the Hyder nomogram was that it
categorized patients who did not undergo a lymphadenectomy as Nx,
instead of N0 like the other prognostic models. Other staging systems,
such as those examined in the current study, were proposed as an
alternative to the AJCC and included the Liver Cancer Study Group of
Japan (LCSGJ),14 the Society of Hepatobiliary Surgery Japan
(SHPBSJ),15 Okabayashi et al,16 and Nathan et al staging systems.17
Similar to nomograms, these staging systems sought to better
differentiate prognosis among patients and more individualized
prognostication. One difference in the SHPBSJ and the Okabayashi
staging systems versus the other staging systems was the inclusion of
only patients with mass-forming ICC, the most common ICC
morphology.15,16 Although the prognostic models differed consider-
ably and used different cut-offs and units for the variables, the
included factors included in the models had marked overlap. As stated
before, vascular invasion, lymph node metastases and number of
lesions were included in all prognostic models. These risk factors have
been associated with worse prognosis in many previous studies.10 On
the other hand, age and cirrhosis were included only in the nomogram
by Hyder et al.13 Interestingly, tumor size was been removed from the
T-stage in the 7th edition of the AJCC staging system, butwas included
in four out of the seven prognostic models, indicating its importance in
prognostication. To this point, tumor size has been re-introduced into
the new, recently published 8th edition AJCC ICC staging system.
Due to the low incidence of ICC compared with other HPB
malignancies, derivation studies for prognostic models often have lacked
statistical power. Underpowered studies are at a risk of over-fitting the
model to the data, causing decreased reproducibility. The current study is
important because it externally evaluated current ICCmodels in a large and
multicenter cohort. In particular, the data suggested that most prognostic
models lackedtheability to identifypatientswithhigherriskof recurrenceor
mortality, as demonstrated by the relatively low c-statistic associated with
the different models. In previous studies by Doussot et al and Nathan et al
similar poor results were demonstrated, although the sample size of the
study cohorts were smaller than the current study.10,17 Although multiple
well-known prognostic factors are used in the prognostic models, accurate
estimation of their impact on survival remains elusive. Themost commonly
used prognostic factors were patient- and tumor-specific factors, with a
limitednumberof factorssuchasnumberof tumorsandvascular invasion. In
addition, these factors were often analyzed in a binary fashion in many
models, further limiting their predictive ability. It stands to reason that the
potential prognostication of ICC, a complex biological process, based on a
small number of binary predictorswhose impact has only beenmeasured in
small cohorts, is limited.
In order to improve the predictive ability of current and new
prognosticmodels, new determinants of biological processes in the form
of biomarkers will be needed. Biomakers such as CEA and CA19-9 have
previously been correlated with tumor processes and clinical out-
comes.31,32 Only the Wang nomogram, however, utilized these
biomarkers in a prognostic model. The superior discriminating ability of
theWangnomogrammay relate to the importanceof thesebiomarkers in
prognostic models. In addition, a recent meta-analysis identified several
other immunohistochemistry biomarkers associated with ICC.33 To this
end, some investigators have proposed that a composite biomarker
profile that combines clinical factors (CEAandCA19-9)with pathological
biomarkers may improve the accuracy of prognostic models and guide
treatment in patients with resected ICC.34 The potential of this approach
hasbeenprovenwith the recent successesof biomarkerbasedprediction
in breast cancer and colorectal cancer.35,36
Results of the current study should be interpreted in the context of
several limitations. The inclusionofmultiple centers didnot allow for the
standardization of operative approach or treatment-based protocols.
The multi-center nature of the study does add to the generalizability,
allowing the findings to be applied across a wide range of patient
populations. Another limitation was the unavailability of preoperative
values of CEA and CA19-9 in a number of patients. The lack of CEA and
CA19-9 data were likely related to the varied clinical practice across
centers, aswell as the relatively recent identificationofCEAandCA19-9
as important prognostic factors. These missing values were unlikely to
change the conclusions of the study, as multiple imputation analysis led
to the same results. Additionally, due to the small number of patients
with a tumormorphology other thanmass-forming ICC,wewere unable
toassessprognosticmodels for eachmorphology separately. Finally, not
all patientsunderwent lymphadenectomyandtherefore the “true”nodal
status of these patients could not be determined. It is likely that a subset
of these patients did indeed harbor occult nodal metastases.
In conclusion,while theWangnomogramhad thebest discriminatory
ability relative to OS and DFS, no staging system or nomogram
demonstrated excellent prognostic discrimination. The most widely
adopted AJCC staging for ICC performed reasonably compared with
other prognostic models, although its overall discrimination was only
modest-to-good. Further research into theoptimizationof ICCprognostic
models, possibly with inclusion of specific biomarkers, is warranted.
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